Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Zhiwei Peter Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6465-7779; OpenAlex author ID A5100449964, A5108050158. Sources: OpenAlex.

Their work

Papers
26 (first author 3, last author 16)
Trials
0
Grants
0
Labs led
2
Collaborators
34
Papers, trials and grants by year

2011: 4 papers · 2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 3 papers · 2016: 4 papers · 2017: 3 papers · 2018: 2 papers · 2019: 3 papers · 2020: none · 2021: none · 2022: 2 papers · 2023: none · 2024: 1 paper

Papers 26

  1. FBXO31 is upregulated by METTL3 to promote pancreatic cancer progression via regulating SIRT2 ubiquitination and degradation. Co-author DOI 10.1038/s41419-024-06425-y↗
  2. Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer. Last author DOI 10.1016/j.semcancer.2020.11.004↗
  3. Management of Advanced Pancreatic Cancer through Stromal Depletion and Immune Modulation. Last author DOI 10.3390/medicina58091298↗
  4. PDS5B regulates cell proliferation and motility via upregulation of Ptch2 in pancreatic cancer cells. Last author DOI 10.1016/j.canlet.2019.06.014↗
  5. miR-223 Regulates Cell Proliferation and Invasion via Targeting PDS5B in Pancreatic Cancer Cells. Last author DOI 10.1016/j.omtn.2019.01.009↗
  6. Deciphering role of FGFR signalling pathway in pancreatic cancer. Last author DOI 10.1111/cpr.12605↗
  7. Retraction notice to "Notch-1 induces Epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells". First author DOI 10.1016/j.canlet.2018.03.020↗
  8. miR-7 Suppresses Tumor Progression by Directly Targeting MAP3K9 in Pancreatic Cancer. Co-author DOI 10.1016/j.omtn.2018.08.012↗
  9. The effects of curcumin on proliferation, apoptosis, invasion, and NEDD4 expression in pancreatic cancer. Last author DOI 10.1016/j.bcp.2017.05.014↗
  10. Inhibition of Cell Survival by Curcumin Is Associated with Downregulation of Cell Division Cycle 20 (Cdc20) in Pancreatic Cancer Cells. Co-author DOI 10.3390/nu9020109↗
  11. Role of Notch signaling pathway in pancreatic cancer. Last author PMID 28337369↗
  12. Correlation Between RAB27B and p53 Expression and Overall Survival in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000453↗
  13. Antitumor activity of curcumin is involved in down-regulation of YAP/TAZ expression in pancreatic cancer cells. Last author DOI 10.18632/oncotarget.12596↗
  14. Curcumin inhibits cell growth and invasion and induces apoptosis through down-regulation of Skp2 in pancreatic cancer cells. Last author PMID 27725901↗
  15. Rottlerin exhibits anti-cancer effect through inactivation of S phase kinase-associated protein 2 in pancreatic cancer cells. Last author PMID 27822410↗
  16. Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Last author DOI 10.18632/oncotarget.2714↗
  17. Arsenic Trioxide Inhibits Cell Growth and Invasion via Down- Regulation of Skp2 in Pancreatic Cancer Cells. Last author DOI 10.7314/apjcp.2015.16.9.3805↗
  18. K-ras-driven engineered mouse models for pancreatic cancer. Last author PMID 25636957↗
  19. Curcumin inhibits cell growth and invasion through up-regulation of miR-7 in pancreatic cancer cells. Last author DOI 10.1016/j.toxlet.2014.09.014↗
  20. Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1α in pancreatic cancer cells. Last author DOI 10.2174/1568009614666140226114015↗
  21. Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype. Co-author DOI 10.1002/jcp.24162↗
  22. Targeting pancreatic cancer stem cells for cancer therapy. Last author DOI 10.1016/j.bbcan.2012.06.002↗
  23. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. First author DOI 10.1002/jcb.23150↗
  24. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. First author DOI 10.1016/j.canlet.2011.03.012↗
  25. Pancreatic cancer: understanding and overcoming chemoresistance. Co-author DOI 10.1038/nrgastro.2010.188↗
  26. Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-κB signaling pathways. Co-author DOI 10.1371/journal.pone.0020537↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jun Xia · 8 shared papers, 2012–2024 · strength 0.68
  2. Jingna Su · 6 shared papers, 2015–2017 · strength 0.39
  3. Xuyuan Yin · 6 shared papers, 2015–2017 · strength 0.39
  4. Jia Ma · 5 shared papers, 2014–2019 · strength 0.39
  5. Xiuxia Zhou · 5 shared papers, 2015–2017 · strength 0.33
  6. Fazlul H. Sarkar · 7 shared papers, 2011–2018 · strength 0.26
  7. Qiang Xu · 1 shared paper, 2022 · strength 0.22
  8. Tiantong Liu · 1 shared paper, 2022 · strength 0.22
  9. Sihang Cheng · 1 shared paper, 2022 · strength 0.22
  10. Sanjeev Banerjee · 6 shared papers, 2011–2018 · strength 0.22
  11. Yiwei Li · 6 shared papers, 2011–2018 · strength 0.22
  12. Asfar Sohail Azmi · 6 shared papers, 2011–2018 · strength 0.22
  13. Yue Cui · 2 shared papers, 2019 · strength 0.21
  14. Jiankun Gao · 3 shared papers, 2011–2017 · strength 0.19
  15. Shadan S. Ali · 5 shared papers, 2011–2018 · strength 0.19
  16. Bin Bao · 5 shared papers, 2011–2018 · strength 0.19
  17. Jia Ma · 1 shared paper, 2024 · strength 0.19
  18. Shangshang Hu · 1 shared paper, 2024 · strength 0.19
  19. Kai Chen · 1 shared paper, 2024 · strength 0.19
  20. Lucio Miele · 5 shared papers, 2011–2018 · strength 0.19
  21. Zheng Han · 1 shared paper, 2022 · strength 0.16
  22. Wangkai Xie · 1 shared paper, 2022 · strength 0.16
  23. Xiaodiao Kang · 1 shared paper, 2019 · strength 0.12
  24. Shisheng Tan · 1 shared paper, 2017 · strength 0.08
  25. Yu Xin Zhang · 1 shared paper, 2017 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.